adalimumab-atto Amjevita
Selected indexed studies
- Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis. (JAMA Dermatol, 2025) [PMID:40042863]
- Navigating adalimumab biosimilars: an expert opinion. (J Comp Eff Res, 2023) [PMID:37855223]
- Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. (JAMA Dermatol, 2025) [PMID:40465280]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AVT02: An Adalimumab Biosimilar. (2022) pubmed
- FKB327: An Adalimumab Biosimilar. (2019) pubmed
- Navigating adalimumab biosimilars: an expert opinion. (2023) pubmed
- GP2017: An Adalimumab Biosimilar. (2018) pubmed
- SB5: An Adalimumab Biosimilar. (2018) pubmed
- Immunogenicity of infliximab and adalimumab. (2019) pubmed
- Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. (2025) pubmed
- Adalimumab-Associated Hemorrhagic Pericarditis. (2020) pubmed
- Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis. (2025) pubmed
- Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto. (2024) pubmed